الفهرس 
Introduction & Aim of the workOnly 14 pages are availabe for public view
 |  | from | 149 |  |  |
| | | from | 149 | | |
Abstract
Sofosbuvir plus daclatasvir, with or without ribavirin achieved a high efficacy (more than 90%) and well tolerated in genotype 4 HCV patients. They were equally effective either in naïve or treatment-experienced patients. Efficacy and safety of sofosbuvir/daclatasvir, with or without ribavirin, were accompanied with attenuation of liver fibrosis score as assessed by FIB-4.
Moreover, single nucleotide polymorphism in the IL-18 gene at -607 could not predict the outcome of HCV infection in Egyptians treated with sofosbuvir/daclatasvir therapy.
In conclusion, the results of the present study reported potential anti-fibrotic effect of either sofosbuvir and/or daclatasvir. Their effects might be attributed, at least partially, to their antioxidant, and anti-inflammatory effects as well as to inhibition of TIMP-1. The study showed no anti-fibrotic effect for high dose of sofosbuvir (double the therapeutic dose); so that HCV patients who are going to use these drugs should adhere to the therapeutic doses and be aware regarding the possible hepatotoxic effect of the large dose of sofosbuvir.